Next Science

Next Science Days Inventory Outstanding

Delisted

The Days Inventory Outstanding (DIO) of Next Science (NXS.AX) as of Oct 28, 2026 is 60.61. In the previous year, Days Inventory Outstanding (DIO) was 44.29 — a change of 36.87% (higher).

Days Inventory Outstanding

60.61

YoY

36.87%

Last updated:

Days Inventory Outstanding (DIO) of Next Science is 2024 60.61 . Days Inventory Outstanding (DIO) of Next Science was 2023 44.29 . It decreases by 36.87% higher compared to the previous year.

The Next Science Days Inventory Outstanding history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Days Inventory Outstanding
Date
Days Inventory Outstanding
Jan 1, 2017
236.54 USD
Jan 1, 2018
304.41 USD
Jan 1, 2019
265.48 USD
Jan 1, 2020
746.58 USD
Jan 1, 2021
272.82 USD
Jan 1, 2022
124.08 USD
Jan 1, 2023
44.29 USD
Jan 1, 2024
60.61 USD
The Next Science Days Inventory Outstanding history
YEARDays Inventory OutstandingYoY
60.61+36.87%
44.29-64.31%
124.08-54.52%
272.82-63.46%
746.58+181.22%
265.48-12.79%
304.41+28.69%
236.54+59.48%
148.32—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Next Science Stock analysis

What does Next Science do? Next Science Ltd. generates revenue through the development and commercialization of its XBIO technology, which addresses bacterial biofilm-related infections in human health. The company's product portfolio includes XPERIENCE, a solution for preventing surgical site infections by rinsing away debris and microorganisms, and SurgX Sterile Antimicrobial Gel, designed to reduce surgical and post-surgical infections through sustained antibacterial action for up to five days. Blast X, an antimicrobial wound gel, targets bacterial infections in wounds. These products are sold to healthcare providers and medical facilities seeking effective solutions for bacterial biofilm eradication and infection prevention. The XBIO technology underpins all products, offering non-toxic efficacy against both biofilm and free-floating bacteria. XPERIENCE is used as a pre-surgical rinse, SurgX provides prolonged protection post-surgery, and Blast X treats existing wounds. Healthcare institutions, particularly hospitals and surgical centers, are the primary buyers, leveraging these products to enhance patient outcomes and reduce infection rates. Next Science Ltd. focuses on the healthcare sector, specifically targeting applications where bacterial biofilms pose significant risks. The company's products are positioned for use in surgical settings, wound care, and infection prevention protocols. By addressing critical needs in medical environments, the firm caters to healthcare providers who prioritize non-toxic, effective antimicrobial solutions for patient safety and operational efficiency. Next Science is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Next Science stock

Days Inventory Outstanding (DIO) of Next Science is 60.61 in 2024.

Days Inventory Outstanding (DIO) of Next Science changed from 44.29 to 60.61, representing a 36.87% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Days Inventory Outstanding (DIO) Next Science since 2006 – with annual values, charts, and detailed analysis.

DIO measures the average number of days inventory is held before being sold. Lower values indicate more efficient inventory management.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Days Inventory Outstanding (DIO)'s Next Science with sector peers and the industry average to assess whether it is attractive.

To evaluate Days Inventory Outstanding (DIO)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Days Inventory Outstanding (DIO).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Next Science

All Key Metrics — Next Science